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encephalopathy 36.7% (33/90), lungs infection and abdominal infection 17.8% (16/90), hepatorenal syndrome 23.3% (21/90), as well as alimentary tract hemorrhage 16.7% (15/90). 63 patients totally underwent plasma pheresis, continuous hemofiltration and Molecular Absorbent Recirculating System (MARS) therapy 76 sessions. HBV active replication (HBV DNA positive) occurred in 78.9% of the patients (71/90). 15 patients died within 30 days after Ltx, and the perioperative mortality is 16.7%. Leading post-Ltx complications were lungs infection 41.1% (37/90). There were no primary liver nonfunction and blood vessel complications in all the patients. Biliary complication accounts for 12.2% (11/90).One-year survival is 76.1% (54/71). Lamivudine combined HBIG were used to prevent HBV recurrence, and there was no HBV graft reinfection and hepatitis B recurrence during a mean 23-month follow up period. Conclusion: Acute on chronic hepatitis B patients waiting for Ltx are generally with severe damaged liver function, multiple-organ impairment and inner environment derangement Therefore much should be done to improve organ function so that better inner environment can be obtained before Ltx. While during Surgery, attention should be paid in the maintenance of coagulability and urine output and in the shrinking of operation time. Attention should also be paid to the intensive care of liver, lung and kidney functions, the appropriate living graft volume, the individual use of immunsuppresive agent and the effective prophylaxis for acute lungs injury and secondary infections post-operatively. With sufficient efforts in all the aspects listed above, acute on chronic hepatitis B patients underwent Ltx could expect a satisfactory clinical outcome and a better quality of life. The patients are divided into three group according to the characteristics of tumor: group A (within Milan criteria), group B (extra Milan criteria within UCSF criteria) and group C (beyond UCSF criteria). Accumulative survival rate and tumor-free Survivals were compared among three groups. Result: 1-, 2-, 3-year accumulative survival rate of 103 patients were 84.0%, 70.5% and 60.2%, which were 93.4%, 83.8%, 73.2% in group A (n = 50), 93.3%, 79.4%, 66.2% in group B (n = 17) and 67.0%, 45.5%, 34.1% in group C (n = 36) respectively. There is no difference in long-term survival rate between group A and group B (P = 0.631), while significant difference between group A and group C (P = 0.001) or group B and group C (P = 0.045). Conclusion: HCC fulfilling Milan criteria is best indicated for liver transplantation, and satisfied outcomes can be achieved for the HCC recipients exceeding Milan criteria but within UCSF criteria as well. Prognostic risk factors are tumor staging and microvascular invasion of tumor. Background: Previous results have demonstrated that HBeAg loss and seroconversion rates on ADV therapy were significantly correlated with baseline ALT levels. We present predictors of long-term treatment outcomes, based on both baseline ALT and HBV levels to help optimise patient management.
Methods: Retrospective multivariate analyses assessed the effects in a sub-group of study subjects with baseline ALT >2×ULN and HBV DNA 10 8 copies/mL ontreatment outcomes at Week 208.
Results: Subjects with baseline ALT >2×ULN and HBV DNA 10 8 copies/mL (n = 44) showed superior outcomes compared to other study subjects with the proportion achieving HBV DNA 300 copies/mL (68.18% vs. 52.02%, P = 0.041), HBeAg loss (59.09% vs. 40.87%, P = 0.020), and HBeAg seroconversion (38.64% vs. 23.80%, P = 0.031).
In subjects with baseline ALT >2×ULN and HBV DNA 10 8 copies/mL, and detextable HBV DNA at Week 208 ADVassociated mutations were seen in 3.92% compared to 10.4% in other subjects. Conclusion: High baseline ALT and low baseline HBV DNA were predictive of 4-years treatment outcomes in HBeAg-Positive patients. Long-term outcomes were significantly better in HBeAg-Positive patients with baseline ALT >2×ULN and HBV DNA 10 8 copies/mL. Viruses are one of the major causes of acute respiratory tract illnesses (ARTIs) throughout the world. The classical common viruses causing ARTIs include influenza virus (IFV), parainfluenza viruses 1 4 (PIVs), enterovirus (EV), human rhinovirus (HRV), respiratory syncytial virus (RSV), adenovirus (AdV), and human coronavirus (HCoV) 229E and OC43. The improvement of molecular detection techniques has resulted in the recent identification of several new respiratory viruses, such as human metapneumovirus (hMPV), novel strains of coronaviruses (SARS-CoV, HCoV-NL63 and HCoV-HKU1), human bocavirus (HBoV), and novel polyomaviruses (WUPyV and KIPyV). The frequent emergency of severe diseases caused by respiratory viruses has made viral ARTIs a global health challenge with highpriority. The studies on the immunological features by antigenomics (including epitomics) analysis will provide basis for monitoring epidemic patterns, investigating the epidemiology and developing diagnosis and vaccines. We have developed a comprehensive platform to express and purify the major antigens encoded by IFVs, PIVs, RSV, hMPV, HCoV, AdV, etc. The purified products have been used to the study of respiratory virus antigenome and epitome, which will provide insight into the immunological properties of the viruses.
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The vaccination program is a reliable strategy in controlling the prevalence of influenza epidemics. Due to the frequent variation, the recommended influenza virus strains for vaccine production have to be changed every year based on the surveillance data. Because the preparation of virus seed lots suitable for vaccine production is time-consuming, a simple approach to obtain the vaccine strains rapidly has been a priority topic in influenza vaccine research and development. The emergency of reverse genetic system of influenza virus allows the rapid production of influenza virus from cloned cDNAs and has been becoming a encouraging alternative approach for influenza virus seed generation. However, current reverse genetics techniques to rescue influenza viruses are based on bidirectional RNA Pol I Pol II transcription system, which can not meet to the need of human vaccine production because of low yield. Here we report improved the RNA polymerase II (pol II) promoter of mRNA synthesis have led to a significant higher-yielding vaccine strain production. These improvements pave the way for the reproducible generation of influenza virus vaccine strain and may be applicable to other reverse genetics systems.
